PMID: 11328296May 1, 2001Paper

Long-term follow-up in patients treated with Mini-BEAM as salvage therapy for relapsed or refractory Hodgkin's disease

British Journal of Haematology
A MartínJ F San Miguel

Abstract

Several studies have focused on investigation of the optimal salvage regimen to induce maximum response before autologous stem cell transplantation (ASCT) in patients with relapsed or refractory Hodgkin's disease (HD). However, in most of these studies, the follow-up is relatively short. In the present study, we report on long-term results of 55 consecutive patients with HD who received Mini-BEAM [BCNU (carmustine), etoposide, cytarabine, melphalan] as salvage therapy before ASCT. Eleven patients were refractory to front-line therapy, 17 were partial responders, and 27 patients had relapsed from HD. Twenty-eight patients achieved complete response, and 18 achieved partial response with a median of two cycles of Mini-BEAM, giving a total response rate of 84%. Significant factors predicting poor response (P < 0.05) were: initial treatment with MOPP (mechloroethamine, oncovin, procarbazine, prednisolone), > or = two previous chemotherapy regimens and three disease characteristics at Mini-BEAM treatment: presence of B symptoms, extranodal involvement or low serum albumin. However, only the last two factors retained independent influence on multivariate analysis. In total, 45/55 patients have been transplanted. Median follow-up afte...Continue Reading

References

Jun 1, 1992·British Journal of Haematology·R ChopraA H Goldstone
Feb 1, 1992·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·G P Canellos
Feb 11, 1992·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·D L LongoV T DeVita
Oct 1, 1991·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·D E ReeceC F LeMaistre
Apr 1, 1987·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·F B HagemeisterF Cabanillas
Feb 1, 1995·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·R ColwillA Keating
Mar 1, 1994·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·M G PfreundschuhR Kuse
Dec 1, 1993·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·A P RapoportM A Tanner
Nov 1, 1993·Annals of Oncology : Official Journal of the European Society for Medical Oncology·P J BiermanJ O Armitage
Apr 1, 1993·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·M CrumpD Pantalony
Jul 1, 1995·Annals of Oncology : Official Journal of the European Society for Medical Oncology·C FerméN Chéron
Feb 1, 1997·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·V BonfanteG Bonadonna
Jan 19, 2000·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·A JostingA Engert
Feb 2, 2000·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·F E van LeeuwenB M Aleman

❮ Previous
Next ❯

Citations

Dec 17, 2009·Hematology·John Kuruvilla
Mar 6, 2012·The Oncologist·Radhakrishnan Ramchandren
May 28, 2014·Annals of Hematology·Jorge LabradorRamón García-Sanz
Dec 3, 2014·Hematology/oncology Clinics of North America·Nishitha M Reddy, Miguel-Angel Perales
Jun 21, 2011·Advances in Hematology·S E Richardson, C McNamara
Sep 17, 2004·Leukemia & Lymphoma·Dina IbrahimAyad Al-Katib
Apr 17, 2013·Expert Opinion on Biological Therapy·Tiziana MoscatoMassimo Martino
Aug 9, 2007·Blood Reviews·Amanda F Cashen, Nancy L Bartlett
Aug 8, 2006·British Journal of Haematology·Miguel A CanalesFernando Hernandez-Navarro
Dec 8, 2010·British Journal of Haematology·Stephen DawHamish Wallace
Jan 26, 2011·Blood·John KuruvillaMichael Crump
Aug 30, 2005·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Basak OyanEmin Kansu
Jun 21, 2013·The Cochrane Database of Systematic Reviews·Michaela RanceaNicole Skoetz
Aug 25, 2018·Expert Review of Hematology·Mayur NarkhedeBruce Cheson
Oct 4, 2005·Pediatric Blood & Cancer·Robert S WimmerCindy L Schwartz
Oct 1, 2008·Expert Review of Hematology·Dennis A EichenauerUNKNOWN German Hodgkin Study Group
Jun 1, 2009·Expert Review of Hematology·David Sibon, Pauline Brice
Nov 6, 2010·Expert Opinion on Pharmacotherapy·Bharti Rathore, Marshall E Kadin
Sep 3, 2013·Expert Review of Hematology·Alessandro IsidoriGiuseppe Visani
Apr 4, 2009·The Oncologist·Jason H Mendler, Jonathan W Friedberg
Jun 6, 2020·Journal of the National Comprehensive Cancer Network : JNCCN·Richard T HoppeNdiya Ogba

❮ Previous
Next ❯

Related Concepts

Related Feeds

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.